Sanofi-Aventis sales in Japan to double from 2005 to 2009
Sales of French drug major Sanofi-Aventis' Japanese subsidiary increased 172% to 215.0 billion yen ($2.11 billion) in 2007 from 125.0 billion yen in 2005 thanks to the growth of its anti-platelet agent Plavix (clopidogrel) and Allegra (fexofenadine HCl), an anti-allergic, said Philippe Fauchet, president of the firm at a Tokyo press conference earlier this month.
In addition, the firm's ranking on the Japanese market of 18th in 2005 was boosted to 13th in 2007 and by February this year the company, with annualized turnover of 224.0 billion yen, moved up to 11th position. Mr Fauchet expects the firm will join the top 10 in the Japanese drug market in 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze